Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 2

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 2
---
 treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies; and Botox Cosmetic for temporary improvement in the appearance of moderate to severe platysma bands as well as for the treatment of masseter muscle prominence (MMP). |

| ● | Advanced key late-stage assets with submission of regulatory applications for Rinvoq for the treatment of adults with giant cell arteritis (GCA) and telisotuzumab-vedotin (Teliso-V) for adults with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression as well as positive Phase 3 data for tavapadon as a monotherapy or adjunctive treatment for PD. |

| ● | Strengthened our pipeline with business development, including execution of approximately twenty collaborations, licensing agreements, or other asset acquisitions. These transactions represent the company’s commitment to invest in research and development that will contribute to AbbVie’s long-term growth. |

2025 Proxy Statement |3

| ​             | ​ |
| PROXY SUMMARY | ​ |

Significant long-term value creation

| ​​​                                                                                                                                                         | ​ | ​ | ​​                                                                  | ​ | ​ | ​​​                       |
| ​Market Capitalization                                                                                                                                      | ​ | ​ | ​Quarterly Dividend                                                 | ​ | ​ | ​Total Stockholder Return |
| +$210BN                                                                                                                                                     | ​ | ​ | +235%                                                               | ​ | ​ | +311%                     |
| 10-year increase, adding significant stockholder value                                                                                                      | ​ | ​ | raised to $1.64 per share from $0.49 per share over the last decade | ​ | ​ | over the last decade      |
| ​                                                                                                                                                           | ​ | ​ | ​                                                                   | ​ | ​ | ​                         |
| The measures set forth in this table were calculated as of 12/31/2024 versus 12/31/2014. The quarterly dividend increase is calculated on a declared basis. |   |   |                                                                     |   |   |                           |

Total stockholder return (TSR) AbbVie has a track record of robust total stockholder returns. Over the last decade, AbbVie’s TSR ranks in the top tier of its named peers and surpasses the cumulative total returns of the Standard & Poor’s 500 Index and the NYSE Arca Pharmaceutical Index, as